Quarterly report [Sections 13 or 15(d)]

Schedule of Reconciliation Consolidated Net Loss (Details)

v3.26.1
Schedule of Reconciliation Consolidated Net Loss (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting [Line Items]    
Product Cost of Sales
Gross Profit
Operating Expenses    
Administrative Expenses 1,066,650 841,685
Research and Development Expenses 510,534 1,545,513
Adjustments and Reconciling Items    
Interest and Dividend Income 71,340 62,512
Gain (Loss) on Sales of Marketable Securities 11,782 2,176
Unrealized Gain (Loss) on Marketable Securities 19,294 (1,597)
Change in Fair Value of Derivative Liabilities 510,000 1,284,000
Total Adjustments and Reconciling Items 612,416 1,347,091
Pharmaceuticals Segment [Member]    
Segment Reporting [Line Items]    
Sales
Product Cost of Sales
Gross Profit
Operating Expenses    
Administrative Expenses 106,665 841,685
Research and Development Expenses 18,948 1,545,513
Stock Based Compensation 84,636
Franchise Tax Expense 21,940
Warrant Issuance Expense
Segment Net Loss 147,553 2,471,834
Adjustments and Reconciling Items    
Dividends Paid on Series H Preferred Stock
Interest and Dividend Income 62,512
Gain (Loss) on Sales of Marketable Securities 2,176
Unrealized Gain (Loss) on Marketable Securities (1,597)
Change in Fair Value of Derivative Liabilities 1,284,000
Loss on FMV of Contingent Compensation
Casualty Gain/(Loss)
Total Adjustments and Reconciling Items 1,347,091
Consolidated Net Loss (147,553) (1,124,743)
Computing Technology Segment [Member]    
Segment Reporting [Line Items]    
Sales
Product Cost of Sales
Gross Profit
Operating Expenses    
Administrative Expenses 959,985
Research and Development Expenses 491,586
Stock Based Compensation 58,606
Franchise Tax Expense 197,463
Warrant Issuance Expense
Segment Net Loss 1,707,640
Adjustments and Reconciling Items    
Dividends Paid on Series H Preferred Stock
Interest and Dividend Income 71,340
Gain (Loss) on Sales of Marketable Securities 11,782
Unrealized Gain (Loss) on Marketable Securities 19,294
Change in Fair Value of Derivative Liabilities 510,000
Loss on FMV of Contingent Compensation
Casualty Gain/(Loss)
Total Adjustments and Reconciling Items 612,416
Consolidated Net Loss $ (1,095,224)